|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pierce KL, Premont RT and Lefkowitz RJ:
Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 3:639–650.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dorsam RT and Gutkind JS:
G-protein-coupled receptors and cancer. Nat Rev Cancer. 7:79–94.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koehler JA and Drucker DJ: Activation of
glucagon-like peptide-1 receptor signaling does not modify the
growth or apoptosis of human pancreatic cancer cells. Diabetes.
55:1369–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J,
Liu Y, Yang J and Hong T: Activation of glucagon-like peptide-1
receptor inhibits tumourigenicity and metastasis of human
pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab.
16:850–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao H, Wei R, Wang L, Tian Q, Tao M, Ke
J, Liu Y, Hou W, Zhang L, Yang J, et al: Activation of
glucagon-like peptide-1 receptor inhibits growth and promotes
apoptosis of human pancreatic cancer cells in a cAMP-dependent
manner. Am J Physiol Endocrinol Metab. 306:E1431–E1441. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ayoub WA, Kumar AA, Naguib HS and Taylor
HC: Exenatide-induced acute pancreatitis. Endocr Pract. 16:80–83.
2010. View Article : Google Scholar
|
|
8
|
Lee PH, Stockton MD and Franks AS: Acute
pancreatitis associated with liraglutide. Ann Pharmacother.
45:e222011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iyer SN, Drake AJ III, West RL, Mendez CE
and Tanenberg RJ: Case report of acute necrotizing pancreatitis
associated with combination treatment of sitagliptin and exenatide.
Endocr Pract. 18:e10–e13. 2012. View Article : Google Scholar
|
|
10
|
Elashoff M, Matveyenko AV, Gier B,
Elashoff R and Butler PC: Pancreatitis, pancreatic, and thyroid
cancer with glucagon-like peptide-1-based therapies.
Gastroenterology. 141:150–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh S, Chang HY, Richards TM, Weiner JP,
Clark JM and Segal JB: Glucagonlike peptide 1-based therapies and
risk of hospitalization for acute pancreatitis in type 2 diabetes
mellitus: A population-based matched case-control study. JAMA
Intern Med. 173:534–539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matveyenko AV, Dry S, Cox HI, Moshtaghian
A, Gurlo T, Galasso R, Butler AE and Butler PC: Beneficial
endocrine but adverse exocrine effects of sitagliptin in the human
islet amyloid polypeptide transgenic rat model of type 2 diabetes:
Interactions with metformin. Diabetes. 58:1604–1615. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gier B, Matveyenko AV, Kirakossian D,
Dawson D, Dry SM and Butler PC: Chronic GLP-1 receptor activation
by exendin-4 induces expansion of pancreatic duct glands in rats
and accelerates formation of dysplastic lesions and chronic
pancreatitis in the KrasG12D mouse model. Diabetes.
61:1250–1262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Butler AE, Campbell-Thompson M, Gurlo T,
Dawson DW, Atkinson M and Butler PC: Marked expansion of exocrine
and endocrine pancreas with incretin therapy in humans with
increased exocrine pancreas dysplasia and the potential for
glucagon-producing neuroendocrine tumors. Diabetes. 62:2595–2604.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reubi JC: Peptide receptors as molecular
targets for cancer diagnosis and therapy. Endocr Rev. 24:389–427.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cases AI, Ohtsuka T, Fujino M, Ideno N,
Kozono S, Zhao M, Ohuchida K, Aishima S, Nomura M, Oda Y, et al:
Expression of glucagon-like peptide 1 receptor and its effects on
biologic behavior in pancreatic neuroendocrine tumors. Pancreas.
43:1–6. 2014. View Article : Google Scholar
|
|
17
|
Nakamura T, Ito T, Uchida M, Hijioka M,
Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Jensen RT, et al:
PSCs and GLP-1R: Occurrence in normal pancreas, acute/chronic
pancreatitis and effect of their activation by a GLP-1R agonist.
Lab Invest. 94:63–78. 2014. View Article : Google Scholar
|
|
18
|
Hörsch D, Göke R, Eissele R, Michel B and
Göke B: Reciprocal cellular distribution of glucagon-like peptide-1
(GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic
islets of rat. Pancreas. 14:290–294. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Waser B and Reubi JC: Radiolabelled GLP-1
receptor antagonist binds to GLP-1 receptor-expressing human
tissues. Eur J Nucl Med Mol Imaging. 41:1166–1171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Furukawa T, Kuboki Y, Tanji E, Yoshida S,
Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N and
Shiratori K: Whole-exome sequencing uncovers frequent GNAS
mutations in intraductal papillary mucinous neoplasms of the
pancreas. Sci Rep. 1:1612011. View Article : Google Scholar :
|
|
21
|
Sato N, Mizumoto K, Beppu K, Maehara N,
Kusumoto M, Nabae T, Morisaki T, Katano M and Tanaka M:
Establishment of a new human pancreatic cancer cell line, NOR-P1,
with high angiogenic activity and metastatic potential. Cancer
Lett. 155:153–161. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furukawa T, Duguid WP, Rosenberg L,
Viallet J, Galloway DA and Tsao MS: Long-term culture and
immortalization of epithelial cells from normal adult human
pancreatic ducts transfected by the E6E7 gene of human papilloma
virus 16. Am J Pathol. 148:1763–1770. 1996.PubMed/NCBI
|
|
23
|
Zhang L, Mizumoto K, Sato N, Ogawa T,
Kusumoto M, Niiyama H and Tanaka M: Quantitative determination of
apoptotic death in cultured human pancreatic cancer cells by
propidium iodide and digitonin. Cancer Lett. 142:129–137. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen LF, Lefkowitz RJ, Caron MG and
Cotecchia S: G-protein-coupled receptor genes as protooncogenes:
Constitutively activating mutation of the alpha 1B-adrenergic
receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad
Sci USA. 88:11354–11358. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knudsen LB, Hastrup S, Underwood CR, Wulff
BS and Fleckner J: Functional importance of GLP-1 receptor species
and expression levels in cell lines. Regul Pept. 175:21–29. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ge Y, Yang D, Dai A, Zhou C, Zhu Y and
Wang MW: The putative signal peptide of glucagon-like peptide-1
receptor is not required for receptor synthesis but promotes
receptor expression. Biosci Rep. 34:e001522014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brom M, Joosten L, Oyen WJ, Gotthardt M
and Boerman OC: Radiolabelled GLP-1 analogues for in vivo targeting
of insulinomas. Contrast Media Mol Imaging. 7:160–166. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bodei L, Paganelli G and Mariani G:
Receptor radionuclide therapy of tumors: A road from basic research
to clinical applications. J Nucl Med. 47:375–377. 2006.PubMed/NCBI
|
